NA-Semax Amidate vs Cagrilintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
NA-Semax Amidate
NA-Semax Amidate (N-Acetyl Semax Amidate) is a modified version of Semax with enhanced stability and potency. Also known as NASA, it provides stronger and longer-lasting nootropic effects than standard Semax.
Full details →Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Side-by-Side Comparison
| Aspect | NA-Semax Amidate | Cagrilintide |
|---|---|---|
| Mechanism | Maintains Semax's core actions on BDNF, NGF, and monoamine systems with improved pharmacokinetics. The modifications enhance CNS penetration and extend duration of action. | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. |
| Typical Dosage | Intranasal: 100-600mcg 1-2 times daily. Start with lower doses as it's more potent than standard Semax. | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. |
| Administration | Intranasal spray is most common. Can be used sublingually. More stable than standard Semax in solution. | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. |
| Side Effects | May cause irritability, hair shedding (rare), or overstimulation at high doses. Generally well-tolerated. | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. |
| Best For |